On October 15, 2013 AstraZeneca announced that MedImmune, its global biologics research and development arm, acquired Spirogen, a privately-held biotech company focused on anti-body-drug conjugate technology for use in oncology. VISCHER advised AstraZeneca on Swiss law aspects of the transaction, working alongside AstraZeneca's in-house legal team. MedImmune acquired 100 percent of Spirogen's shares for an initial consideration of USD 200 million and deferred consideration of up to USD 240 million based on reaching predeter-mined development milestones. The VISCHER team was led by partner Dr. Stefan Kohler and included associates Janusz Marty, Dr. Peter Kühn and Nicolas Facincani.